Encure Biotherapeutics is a cardiovascular therapeutics company using AI, quantum‑enhanced modeling, human cardiac organoids, and advanced nanotechnology to discover new targets and design organ‑targeted therapies for complex heart and vascular disease.
By pairing these innovations with patient‑centric, cost‑aware development, Encure aims to deliver effective, affordable therapies that close critical gaps in cardiovascular care and generate sustainable value for patients, health systems, and investors